Department of Dermatology and Allergy and the Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
Department of Dermatology and Allergy and the Copenhagen Research Group for Inflammatory Skin (CORGIS), Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, Denmark.
J Am Acad Dermatol. 2018 Mar;78(3 Suppl 1):S37-S42. doi: 10.1016/j.jaad.2017.12.018. Epub 2017 Dec 15.
The interleukin 13 (IL-13) and IL-31 cytokines and inflammatory pathways have been identified as important for the pathophysiology of atopic dermatitis (AD). Monoclonal antibodies against IL-13 have been studied for the treatment of asthma since 2011. More recently, 2 phase 2 trials have been completed with these antibodies in AD treatment. In both trials, significant reductions of Eczema Area and Severity Index scores were seen. IL-31 is thought to play a role transmitting itch sensation to the central nervous system, and blocking IL-31 activity reduces itch in patients with AD. One phase 2 trial has been completed for a humanized antibody against IL-31 receptor alpha, which is 1 subunit of the IL-31 receptor complex. This study showed significant dose-dependent reductions in pruritus, Eczema Area and Severity Index scores, and markers of sleep quality. Initial clinical trials for monoclonal antibodies against IL-13 and IL-31 receptor A all show promise, although long-term safety and efficacy data are lacking. Nevertheless, these medications will likely play a role in the treatment of moderate-to-severe AD.
白细胞介素 13（IL-13）和 IL-31 细胞因子及炎症途径已被确定为特应性皮炎（AD）发病机制的重要因素。自 2011 年以来，针对 IL-13 的单克隆抗体已被用于哮喘治疗的研究。最近，两项 2 期临床试验已完成，这些抗体用于 AD 的治疗。在这两项试验中，均观察到 Eczema Area and Severity Index（EASI）评分显著降低。IL-31 被认为在将瘙痒感传递到中枢神经系统中起作用，阻断 IL-31 活性可减少 AD 患者的瘙痒感。一项针对 IL-31 受体 alpha 的人源化抗体的 2 期临床试验已经完成，IL-31 受体 alpha 是 IL-31 受体复合物的 1 个亚单位。该研究显示瘙痒、EASI 评分和睡眠质量标志物均呈显著剂量依赖性降低。针对 IL-13 和 IL-31 受体 A 的单克隆抗体的初步临床试验均显示出良好的前景，尽管缺乏长期安全性和疗效数据。然而，这些药物可能在中重度 AD 的治疗中发挥作用。
Zotero 插件